Fat loss
Survodutide
Boehringer Ingelheim's investigational GLP-1 / glucagon dual agonist. Phase 2 weight loss in the 15 to 19% range, with a notable side-effect on liver fibrosis in NASH patients.
€329.99per vial
Choose an option
1
- Pay with Bitcoin
- Discreet shipping within Germany
- Purity-guaranteed batches
- 14-day refund period if unsatisfied
Delivery & guarantee
Orders typically arrive within 3 weeks.
If your delivery arrives late, you'll receive a discount on your next order.
About
Survodutide (formerly BI 456906) is a GLP-1 / glucagon dual agonist sitting between Mazdutide and Retatrutide. The GLP-1 arm handles appetite; the glucagon arm pushes energy expenditure and acts on hepatic fat.
Read the full research guideWhy people choose it
- Phase 2 weight loss of ~15 to 19% at 46 weeks across the dose range
- Meaningful liver-fibrosis improvement in NASH Phase 2 (a stricter endpoint than hepatic fat fraction)
- Glucagon-mediated energy expenditure partially offsets dieting adaptation
- Once-weekly dosing. Fits the existing incretin rhythm
At a glance
- Experience level
- Advanced
- Administration
- Subcutaneous
Sold for laboratory research only. Not for human consumption. No therapeutic claims are made.
Sign in to view this product
Survodutide
Log in or create a free account to see full details and prices.
Don't have an account? Sign up